Asia Bio-Chem Group Corp (ABC) Receiving Somewhat Favorable Press Coverage, Analysis Finds
Media headlines about Asia Bio-Chem Group Corp (NYSE:ABC) have been trending somewhat positive recently, Accern reports. The research group scores the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Asia Bio-Chem Group Corp earned a news impact score of 0.16 on Accern’s scale. Accern also gave headlines about the company an impact score of 45.8211860950645 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s rankings:
- AmerisourceBergen (ABC) Rewards Investors With Dividend Hike (finance.yahoo.com)
- AmerisourceBergen Corporation (Holding Co) (ABC) Expected to Announce Quarterly Sales of $40.26 Billion (americanbankingnews.com)
- AmerisourceBergen Corporation (Holding Co) (ABC) Increases Dividend to $0.38 Per Share (americanbankingnews.com)
- AmerisourceBergen Increases Dividend 4 Percent (finance.yahoo.com)
- Adverse Earnings Visibility Keep AmerisourceBergen (ABC) a Sell – Investorplace.com (investorplace.com)
Several equities research analysts have commented on the company. Cowen and Company upgraded Asia Bio-Chem Group Corp from a “market perform” rating to an “outperform” rating in a research note on Tuesday, October 10th. Jefferies Group LLC set a $85.00 price objective on Asia Bio-Chem Group Corp and gave the stock a “hold” rating in a research note on Sunday, October 29th. Zacks Investment Research lowered Asia Bio-Chem Group Corp from a “hold” rating to a “sell” rating in a research note on Tuesday, October 3rd. Leerink Swann set a $90.00 price objective on Asia Bio-Chem Group Corp and gave the stock a “buy” rating in a research note on Monday, August 7th. Finally, Morgan Stanley lowered Asia Bio-Chem Group Corp from an “overweight” rating to an “equal weight” rating in a research note on Thursday, September 14th. One analyst has rated the stock with a sell rating, seven have given a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of C$90.94.
Shares of Asia Bio-Chem Group Corp (NYSE ABC) traded down C$0.25 during trading on Friday, reaching C$75.00. The company had a trading volume of 3,010,000 shares, compared to its average volume of 2,200,000. Asia Bio-Chem Group Corp has a 52 week low of C$71.90 and a 52 week high of C$97.85.
Asia Bio-Chem Group Corp (NYSE:ABC) last issued its quarterly earnings data on Thursday, November 2nd. The company reported C$1.33 earnings per share for the quarter, topping the consensus estimate of C$1.32 by C$0.01. The company had revenue of C$39.12 billion during the quarter, compared to analyst estimates of C$40.10 billion. Asia Bio-Chem Group Corp had a negative return on equity of 50.63% and a negative net margin of 0.75%. The firm’s revenue for the quarter was up 4.2% compared to the same quarter last year. During the same period in the prior year, the business posted $1.30 earnings per share.
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 4th. Investors of record on Monday, November 20th will be given a $0.38 dividend. This represents a $1.52 annualized dividend and a yield of 2.03%. This is a positive change from Asia Bio-Chem Group Corp’s previous quarterly dividend of $0.37. The ex-dividend date is Friday, November 17th.
In other Asia Bio-Chem Group Corp news, Chairman Steven H. Collis sold 15,000 shares of the company’s stock in a transaction on Friday, September 1st. The stock was sold at an average price of C$79.92, for a total transaction of C$1,198,800.00. Following the transaction, the chairman now directly owns 253,876 shares in the company, valued at C$20,289,769.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Tim G. Guttman sold 11,600 shares of the company’s stock in a transaction on Wednesday, September 20th. The stock was sold at an average price of C$79.47, for a total value of C$921,852.00. The disclosure for this sale can be found here. Insiders sold 115,627 shares of company stock valued at $9,057,646 over the last quarter.
WARNING: “Asia Bio-Chem Group Corp (ABC) Receiving Somewhat Favorable Press Coverage, Analysis Finds” was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The legal version of this piece can be viewed at https://www.dailypolitical.com/2017/11/11/asia-bio-chem-group-corp-abc-receiving-somewhat-favorable-press-coverage-analysis-finds.html.
Asia Bio-Chem Group Corp Company Profile
AmerisourceBergen Corporation is a pharmaceutical sourcing and distribution services company. The Company’s segments include Pharmaceutical Distribution and Other. The Company provides services to healthcare providers, and pharmaceutical and biotech manufacturers. As of June 30, 2016, the Pharmaceutical Distribution segment consists of two operating segments, including the operations of AmerisourceBergen Drug Corporation (ABDC) and AmerisourceBergen Specialty Group (ABSG), which distributes specialty drugs to their customers.
Receive News & Ratings for Asia Bio-Chem Group Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asia Bio-Chem Group Corp and related companies with MarketBeat.com's FREE daily email newsletter.